Bio

Clinical Focus


  • Cancer > Cutaneous (Dermatologic) Oncology
  • Dermatology

Academic Appointments


Honors & Awards


  • Mentorship Award, Women?s Dermatologic Society (2013)
  • Peter E. Pochi Award for Excellent in Dermatology, Boston University School of Medicine (2010)

Professional Education


  • Board Certification: Dermatology, American Board of Dermatology (2014)
  • Internship:Stanford University
  • Residency:Loma Linda University
  • Medical Education:Boston University School of Medicine (2010)

Publications

All Publications


  • Cosmetic benefits of natural ingredients. Journal of drugs in dermatology : JDD Bowe, W. P., Pugliese, S. 2014; 13 (9): 1021-5

    Abstract

    Photoaging is a leading concern for patients and many of these patients will express a desire to utilize natural ingredients as treatment. Mushrooms, feverfew, green tea, licorice, olive oil, soy, and coffee berry have been shown to have antioxidant properties and may play a role in the treatment and prevention of photoaging. In this manuscript, the most recent select basic science and clinical studies examining the mechanisms and efficacy of these ingredients will be discussed.

    J Drugs Dermatol. 2014;13(9):1021-1025.

    View details for PubMedID 25226001

  • Favre-Racouchot Syndrome Acneiform Eruptions in Dermatology Zeichner, J. A., Pugliese , S., Smith, A., Epstein, R., Torres, A. Springer Publishing. 2013: 253-257
  • Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Talpur, R., Demierre, M. F., Geskin, L., Baron, E., Pugliese, S., Eubank, K., Zic, J. A., Miller, D. R., Tharp, M., Bohjanen, K., Duvic, M. 2011; 11 (2): 219-227

    Abstract

    To demonstrate the efficacy of the UVAR XTS Photopheresis System and evaluate health-related quality of life in patients with early-stage mycosis fungoides (MF).Extracorporeal photopheresis was administered 2 days every 4 weeks for 6 months. Patients with partial responses by skin weighted assessment continued for 6 months; nonresponders added oral bexarotene and/or interferon ?. Health-related quality of life was assessed at baseline and every 3 months with 3 validated tools.Nineteen patients with early-stage MF (7 men, 12 women; 16 white, 3 African Americans) with median age of 63.5 years (range, 46-85 years) participated. Their stages were IA (n = 3), IB (n = 14), and IIA (n = 2). The overall response rate for extracorporeal photopheresis (ECP) alone, was 42% (8/19; including 7 partial response, 1 complete response), with a median of 12 ECP sessions (range, 3-32) given over a median of 12 months (3-32 months) and with an overall duration of response of 6.5 months (range, 1-48 months). Seven patients with stable disease at 3 months received additional bexarotene (3/5; 1 complete response) or bexarotene plus interferon ? (1/2), and 4 (57%) of 7 responded. Treatment-related adverse effects were limited to those expected with interferon (fatigue, nausea, vomiting, and diarrhea), or with hypertriglyceridemia and bexarotene. Trends in health-related quality of life indicated an improvement in emotional scores over time.ECP is effective for patients with early-stage MF alone or in combination with biologic response modifiers with low toxicity and improved quality of life.

    View details for DOI 10.1016/j.dml.2011.03.003

    View details for Web of Science ID 000291235900006

    View details for PubMedID 21575927

  • Adverse Reaction to Cutaneous Injection of Contents From a Vitamin E Liquid-Containing Capsule ARCHIVES OF DERMATOLOGY Pugliese, S., Yaar, R., Al-Dawsari, N., Goldberg, L. J., Garg, A. 2010; 146 (4): 454-455

    View details for Web of Science ID 000276813500028

    View details for PubMedID 20404248

Footer Links:

Stanford Medicine Resources: